search
Back to results

Dietary Modulation of Neuroinflammation in Age-Related Memory Disorders

Primary Purpose

Memory Loss, Inflammation

Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
650 mg of Cocoapro flavanols
0 mg of Cocoapro flavanols
Sponsored by
Columbia University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Memory Loss focused on measuring Flavanol, Cocoapro

Eligibility Criteria

50 Years - 69 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Signed and dated informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal screening or management of the subject).
  2. Healthy Male or Female subjects. (Females must be post-menopausal)
  3. Age between 50 and 69 years, both inclusive.
  4. Body mass index between 18.0 and 35 kg/m², both inclusive.

Exclusion Criteria:

  1. Currently undergoing medical treatment, including prescription drugs/medication.
  2. Clinically significant abnormal hematology, biochemistry, urinalysis, or coagulation screening tests, as judged by the Investigator.
  3. History or presence of cancer (except basal cell skin cancer or squamous cell skin cancer), or any clinically significant cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological (with the exception euthyroid struma), haematological, dermatological, venereal, neurological, psychiatric diseases or other major disorders as judged by the Investigator.
  4. Seated blood pressure at screening (after resting for 5 min in seated position) outside the range of 90-140 mmHg for systolic or 50-90 mmHg for diastolic (excluding white-coat hypertension; therefore, if a repeated measurement shows values within the range, the subject can be included in the trial) and/or resting supine heart rate outside the range 50-90 beats per minute. Measurement taken at consent before eligibility is determined
  5. Heart Diseases.
  6. Hepatitis B or C positive status.
  7. HIV positive status.
  8. History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction.
  9. Use of non-prescription medication, herbal products or nutritional supplements during the study, and within the last 4 weeks before the start of the study (screening), as judged by the Investigator; occasional use of aspirin, ibuprofen, acetaminophen is permitted.
  10. Adherence to a vegan or vegetarian diet or to specialty/uncommon diets.
  11. Food Allergies to tree nuts, soy, cocoa and cocoa-containing products.
  12. People who choose to avoid caffeine intake.
  13. Current or history of alcoholism or drug/chemical abuse as per Investigator's judgment.
  14. Hormone Replacement Therapy; Currently pregnant; Pregnant or Interview\ lactating within past 6 months; Hormonal birth control (pill).
  15. Smoking.
  16. Unwilling to have blood drawn or anxiety/nausea during a blood draw.
  17. Uncomfortable completing memory and attention tasks in the English language
  18. Montreal Cognitive Assessment (MoCA) score less than 26.
  19. Inability to swallow study capsules Interview (at Consent)
  20. Did not complete the two weeks Run-In Period (Participants who missed more than 2 intake occasions out of 14 days (28 occasions total) or if there are > 8 capsules left in the bottle after the two weeks will be excluded).

MRI RELATED

  1. Cardiac Pacemaker
  2. Internal Pump
  3. Insulin Pump
  4. Tattoo eyeliner
  5. Wire sutures
  6. Internal Metal Objects
  7. Metal Slivers in Eye
  8. Prosthesis
  9. Hearing Aid Implants
  10. Neurostimulator
  11. Metal Fragments
  12. Brain Aneurysm Clips
  13. Vascular Clips
  14. Breast Expander
  15. Vena Cava Filter
  16. Heart Valve
  17. Metal Stents
  18. Asthmatic symptoms within the past 3 years
  19. Sickle Cell Disease

Sites / Locations

  • Columbia University Irving Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

650 mg of Cocoapro flavanols

0mg Cocoapro flavanols

Arm Description

Daily, each subject will consume either two cocoa flavanol-containing capsules twice a day with a meal.

Daily, each subject will consume either ttwo placebo-containing capsules twice a day with a meal.

Outcomes

Primary Outcome Measures

HMGB1
circulating levels of the inflammatory marker HMGB1

Secondary Outcome Measures

NFkB
TLR4-dependent NFkB
TNFa
TLR4-dependent TNFa

Full Information

First Posted
October 24, 2018
Last Updated
October 12, 2023
Sponsor
Columbia University
Collaborators
National Institute on Aging (NIA)
search

1. Study Identification

Unique Protocol Identification Number
NCT03723694
Brief Title
Dietary Modulation of Neuroinflammation in Age-Related Memory Disorders
Official Title
Dietary Modulation of Neuroinflammation in Age-Related Memory Disorders
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
January 1, 2019 (Actual)
Primary Completion Date
January 2024 (Anticipated)
Study Completion Date
June 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Columbia University
Collaborators
National Institute on Aging (NIA)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to test the effect of a cocoa-derived dietary flavanol on brain structures and cognitive outcomes in a 12-week randomized controlled trial of 146 healthy participants, age 50-69, who will receive this cocoa derivative or a placebo. Th investigators will also examine the role of inflammation in this relationship.
Detailed Description
Within 25 years, the US population aged 65 and over will double in size to 80 million bringing, with it an epidemic of aging-related cognitive decline, from normal cognitive aging to neurodegenerative disorders including Alzheimer's Disease. These conditions impair quality of life and functional status, impose an enormous burden on individuals, their families, the healthcare system, and require elucidation of mechanisms and development of new treatments to prevent or at least slow their progression. The use of plant-based food and drink for health purposes has a long and well-documented history. Cocoa beans contain a substance that has multiple beneficial health effects. In this study, the investigators will test the effect of this substance on brain structures and cognitive outcomes in a 12-week randomized controlled trial of 146 healthy participants, age 50-69, who will receive this cocoa derivative or a placebo. The investigators also will examine the role of inflammation in this relationship. Such a trial has potential for significant clinical impact.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Memory Loss, Inflammation
Keywords
Flavanol, Cocoapro

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
146 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
650 mg of Cocoapro flavanols
Arm Type
Active Comparator
Arm Description
Daily, each subject will consume either two cocoa flavanol-containing capsules twice a day with a meal.
Arm Title
0mg Cocoapro flavanols
Arm Type
Placebo Comparator
Arm Description
Daily, each subject will consume either ttwo placebo-containing capsules twice a day with a meal.
Intervention Type
Dietary Supplement
Intervention Name(s)
650 mg of Cocoapro flavanols
Intervention Description
12-week period during which participant will be asked to consume two cocoa-flavanol-containing capsules(650mg) twice a day with meals.
Intervention Type
Dietary Supplement
Intervention Name(s)
0 mg of Cocoapro flavanols
Intervention Description
12-week period during which participant will be asked to consume two cocoa-flavanol-containing capsules(0mg) twice a day with meals.
Primary Outcome Measure Information:
Title
HMGB1
Description
circulating levels of the inflammatory marker HMGB1
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
NFkB
Description
TLR4-dependent NFkB
Time Frame
12 weeks
Title
TNFa
Description
TLR4-dependent TNFa
Time Frame
12 weeks
Other Pre-specified Outcome Measures:
Title
ModBent
Description
modified Benton Recognition Task
Time Frame
12 weeks
Title
ModRey
Description
Modified Rey Auditory Verbal Learning Test
Time Frame
12 weeks
Title
multiple cognitive domains
Description
NIH Toolbox Cognition Battery, which includes adaptive computerized tests of executive function, attention, episodic memory, language, processing speed, and working memory
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
69 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Signed and dated informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal screening or management of the subject). Healthy Male or Female subjects. (Females must be post-menopausal) Age between 50 and 69 years, both inclusive. Body mass index between 18.0 and 35 kg/m², both inclusive. Exclusion Criteria: Currently undergoing medical treatment, including prescription drugs/medication. Clinically significant abnormal hematology, biochemistry, urinalysis, or coagulation screening tests, as judged by the Investigator. History or presence of cancer (except basal cell skin cancer or squamous cell skin cancer), or any clinically significant cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological (with the exception euthyroid struma), haematological, dermatological, venereal, neurological, psychiatric diseases or other major disorders as judged by the Investigator. Seated blood pressure at screening (after resting for 5 min in seated position) outside the range of 90-140 mmHg for systolic or 50-90 mmHg for diastolic (excluding white-coat hypertension; therefore, if a repeated measurement shows values within the range, the subject can be included in the trial) and/or resting supine heart rate outside the range 50-90 beats per minute. Measurement taken at consent before eligibility is determined Heart Diseases. Hepatitis B or C positive status. HIV positive status. History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction. Use of non-prescription medication, herbal products or nutritional supplements during the study, and within the last 4 weeks before the start of the study (screening), as judged by the Investigator; occasional use of aspirin, ibuprofen, acetaminophen is permitted. Adherence to a vegan or vegetarian diet or to specialty/uncommon diets. Food Allergies to tree nuts, soy, cocoa and cocoa-containing products. People who choose to avoid caffeine intake. Current or history of alcoholism or drug/chemical abuse as per Investigator's judgment. Hormone Replacement Therapy; Currently pregnant; Pregnant or Interview\ lactating within past 6 months; Hormonal birth control (pill). Smoking. Unwilling to have blood drawn or anxiety/nausea during a blood draw. Uncomfortable completing memory and attention tasks in the English language Montreal Cognitive Assessment (MoCA) score less than 26. Inability to swallow study capsules Interview (at Consent) Did not complete the two weeks Run-In Period (Participants who missed more than 2 intake occasions out of 14 days (28 occasions total) or if there are > 8 capsules left in the bottle after the two weeks will be excluded). MRI RELATED Cardiac Pacemaker Internal Pump Insulin Pump Tattoo eyeliner Wire sutures Internal Metal Objects Metal Slivers in Eye Prosthesis Hearing Aid Implants Neurostimulator Metal Fragments Brain Aneurysm Clips Vascular Clips Breast Expander Vena Cava Filter Heart Valve Metal Stents Asthmatic symptoms within the past 3 years Sickle Cell Disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Richard P. Sloan, PhD
Organizational Affiliation
Columbia University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Columbia University Irving Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
25344629
Citation
Brickman AM, Khan UA, Provenzano FA, Yeung LK, Suzuki W, Schroeter H, Wall M, Sloan RP, Small SA. Enhancing dentate gyrus function with dietary flavanols improves cognition in older adults. Nat Neurosci. 2014 Dec;17(12):1798-803. doi: 10.1038/nn.3850. Epub 2014 Oct 26.
Results Reference
background

Learn more about this trial

Dietary Modulation of Neuroinflammation in Age-Related Memory Disorders

We'll reach out to this number within 24 hrs